Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1955 1
1965 13
1966 10
1967 19
1968 25
1969 21
1970 20
1971 22
1972 35
1973 40
1974 41
1975 45
1976 48
1977 48
1978 42
1979 41
1980 78
1981 64
1982 50
1983 79
1984 99
1985 118
1986 115
1987 126
1988 138
1989 122
1990 166
1991 126
1992 98
1993 121
1994 126
1995 134
1996 194
1997 197
1998 181
1999 235
2000 250
2001 257
2002 330
2003 384
2004 429
2005 509
2006 546
2007 568
2008 580
2009 634
2010 679
2011 761
2012 817
2013 931
2014 994
2015 941
2016 880
2017 842
2018 848
2019 908
2020 1011
2021 1202
2022 1288
2023 1251
2024 486

Text availability

Article attribute

Article type

Publication date

Search Results

19,004 results

Results by year

Filters applied: . Clear all
Page 1
The treatment landscape of metastatic prostate cancer.
Yamada Y, Beltran H. Yamada Y, et al. Cancer Lett. 2021 Oct 28;519:20-29. doi: 10.1016/j.canlet.2021.06.010. Epub 2021 Jun 18. Cancer Lett. 2021. PMID: 34153403 Free PMC article. Review.
[Vorwort].
von Amsberg G, Gschwend JE. von Amsberg G, et al. Oncol Res Treat. 2020;43 Suppl 2:5. doi: 10.1159/000507053. Epub 2020 May 19. Oncol Res Treat. 2020. PMID: 32428911 Free article. German. No abstract available.
Drug therapy of prostatic cancer.
Huben RP, Perrapato SD. Huben RP, et al. Drugs Aging. 1991 Sep-Oct;1(5):353-63. doi: 10.2165/00002512-199101050-00003. Drugs Aging. 1991. PMID: 1838950 Review.
Androgen receptor signaling regulates DNA repair in prostate cancers.
Polkinghorn WR, Parker JS, Lee MX, Kass EM, Spratt DE, Iaquinta PJ, Arora VK, Yen WF, Cai L, Zheng D, Carver BS, Chen Y, Watson PA, Shah NP, Fujisawa S, Goglia AG, Gopalan A, Hieronymus H, Wongvipat J, Scardino PT, Zelefsky MJ, Jasin M, Chaudhuri J, Powell SN, Sawyers CL. Polkinghorn WR, et al. Cancer Discov. 2013 Nov;3(11):1245-53. doi: 10.1158/2159-8290.CD-13-0172. Epub 2013 Sep 11. Cancer Discov. 2013. PMID: 24027196 Free PMC article.
Adherence to Hormonal Therapies in Prostate Cancer.
Hafron J, Sangha P, Kung T, Pruett J. Hafron J, et al. Urol Pract. 2023 Nov;10(6):540-546. doi: 10.1097/UPJ.0000000000000445. Epub 2023 Aug 30. Urol Pract. 2023. PMID: 37647139 Review.
Efficacy and Safety of Autologous Dendritic Cell-Based Immunotherapy, Docetaxel, and Prednisone vs Placebo in Patients With Metastatic Castration-Resistant Prostate Cancer: The VIABLE Phase 3 Randomized Clinical Trial.
Vogelzang NJ, Beer TM, Gerritsen W, Oudard S, Wiechno P, Kukielka-Budny B, Samal V, Hajek J, Feyerabend S, Khoo V, Stenzl A, Csöszi T, Filipovic Z, Goncalves F, Prokhorov A, Cheung E, Hussain A, Sousa N, Bahl A, Hussain S, Fricke H, Kadlecova P, Scheiner T, Korolkiewicz RP, Bartunkova J, Spisek R; VIABLE Investigators. Vogelzang NJ, et al. JAMA Oncol. 2022 Apr 1;8(4):546-552. doi: 10.1001/jamaoncol.2021.7298. JAMA Oncol. 2022. PMID: 35142815 Free PMC article. Clinical Trial.
The Efficacy and Safety of Metastasis-directed Therapy in Patients with Prostate Cancer: A Systematic Review and Meta-analysis of Prospective Studies.
Miszczyk M, Rajwa P, Yanagisawa T, Nowicka Z, Shim SR, Laukhtina E, Kawada T, von Deimling M, Pradere B, Rivas JG, Gandaglia G, van den Bergh RCN, Goldner G, Supiot S, Zilli T, Trinh QD, Nguyen PL, Briganti A, Ost P, Ploussard G, Shariat SF. Miszczyk M, et al. Eur Urol. 2024 Feb;85(2):125-138. doi: 10.1016/j.eururo.2023.10.012. Epub 2023 Nov 7. Eur Urol. 2024. PMID: 37945451 Free article. Review.
19,004 results
You have reached the last available page of results. Please see the User Guide for more information.